CGT
INJECTION
DUAL CHAMBER
FORMULATION
PFS
WEARABLES
ALL INJECTION
OCULAR
ORAL
RESPIRATORY
PULMONARY
NASAL
ALL RESPIRATORY
SUSTAINABILITY
MORE
EXPERT VIEWS
INTERVIEWS
EARLY INSIGHTS
COMPANY LISTINGS
OUR AUTHORS
EVENTS
ED CALENDAR
CONTRIBUTE
MEDIA PACK 2026
Subscribe
CGT
INJECTION
DUAL CHAMBER
FORMULATION
PFS
WEARABLES
ALL INJECTION
OCULAR
ORAL
RESPIRATORY
PULMONARY
NASAL
ALL RESPIRATORY
SUSTAINABILITY
MORE
EXPERT VIEWS
INTERVIEWS
EARLY INSIGHTS
COMPANY LISTINGS
OUR AUTHORS
EVENTS
ED CALENDAR
CONTRIBUTE
MEDIA PACK 2026
SEARCH
SEARCH
advanced search
Clare Holden
Vice-President, Research & Development, Infusion Care
Is this your profile?
About
Clare Holden, Vice-President, Research & Development, Infusion Care. Clare has been with the company since 2019 and has held a variety of leadership roles including in R&D for Continence Care and Ostomy Care.
Contributions
INJECTION
ADVANCING SUBCUTANEOUS INFUSION THERAPY FOR PATIENTS THROUGH INNOVATION AND PARTNERSHIPS
Julien Vandewalle and Clare Holden explain Convatec’s long-term partnerships with pharmaceutical and medical device companies are driving development in chronic care by introducing subcutaneous technologies that support the treatment of conditions such as diabetes and Parkinson’s disease – showcasing Convatec’s Neria™ Guard infusion set.
Top
